| Primary information |
|---|
| ID | antitb_1198, |
| Name | 24915878 |
| N-Terminal modification | Pinanediol PD-protected Boropentapeptide |
| C-Terminal Modification | AVKAA-BO2(PD) |
| Chemical Modification | Free |
| Linear/Cyclic | Conjugated with Boronic acid and pinanediol PD |
| Length | Conjugated with Boronic acid and pinanediol PD |
| Chirality | Linear |
| Nature | 5 |
| Source | L |
| Species | Synthetic |
| Inhibition Concentration | Mycobacterium thermoresistible |
| In Vitro/ In vivo | Mycobacterium thermoresistible |
| Cell Line | IC50 = 121.6 ± 25.3 μM for MycP1 |
| Inhibition Concentration | In vitro |
| Sequence | 2014 |
| Cytotoxicity | None |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | None |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Inhibit enzyme (MycP1) reponsible for cleavage of virulence factor (ESX secretion-associated protein B (EspB)) |
| Other activities | Mycosin protease-1 (MycP1) |
| PMID | None |
| Year of Publication | None |
Tertiary Structure
(Technique) | Not Predicted), |
| Primary information |
|---|
| ID | antitb_1199, |
| Name | 24915878 |
| N-Terminal modification | Pinanediol PD-protected Boropentapeptide |
| C-Terminal Modification | AVKAA-BO2(PD) |
| Chemical Modification | Free |
| Linear/Cyclic | Conjugated with Boronic acid and pinanediol PD |
| Length | Conjugated with Boronic acid and pinanediol PD |
| Chirality | Linear |
| Nature | 5 |
| Source | L |
| Species | Synthetic |
| Inhibition Concentration | Mycobacterium smegmatis |
| In Vitro/ In vivo | Mycobacterium smegmatis |
| Cell Line | IC50 = 93.2±33.7 μM for MycP2 |
| Inhibition Concentration | In vitro |
| Sequence | 2014 |
| Cytotoxicity | None |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | None |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Inhibit enzyme (MycP1) reponsible for cleavage of virulence factor (ESX secretion-associated protein B (EspB)) |
| Other activities | Mycosin protease-1 (MycP1) |
| PMID | None |
| Year of Publication | None |
Tertiary Structure
(Technique) | Not Predicted), |
| Primary information |
|---|
| ID | antitb_1200, |
| Name | 24915878 |
| N-Terminal modification | Pinanediol PD-protected Boropentapeptide |
| C-Terminal Modification | AVKAA-BO2(PD) |
| Chemical Modification | Free |
| Linear/Cyclic | Conjugated with Boronic acid and pinanediol PD |
| Length | Conjugated with Boronic acid and pinanediol PD |
| Chirality | Linear |
| Nature | 5 |
| Source | L |
| Species | Synthetic |
| Inhibition Concentration | Mycobacterium tuberculosis |
| In Vitro/ In vivo | Mycobacterium tuberculosis |
| Cell Line | IC50 = 37.9±5.2 μM for MycP3 |
| Inhibition Concentration | In vitro |
| Sequence | 2014 |
| Cytotoxicity | None |
| In vivo Model | NA |
| Lethal Dose | NA |
| Immune Responce | None |
| Mechanism of Action | NA |
| Target | NA |
| Combination Therapy | Inhibit enzyme (MycP1) reponsible for cleavage of virulence factor (ESX secretion-associated protein B (EspB)) |
| Other activities | Mycosin protease-1 (MycP1) |
| PMID | None |
| Year of Publication | None |
Tertiary Structure
(Technique) | Not Predicted), |